Search details
1.
Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
Oncologist
; 29(4): e561-e569, 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38007400
2.
A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Histopathology
; 78(4): 567-577, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-32936950
3.
Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.
J Med Internet Res
; 22(12): e18655, 2020 12 21.
Article
in English
| MEDLINE | ID: mdl-33346738
4.
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
Mod Pathol
; 30(2): 217-226, 2017 02.
Article
in English
| MEDLINE | ID: mdl-27767099
5.
Butyrophilin Btn2a2 inhibits TCR activation and phosphatidylinositol 3-kinase/Akt pathway signaling and induces Foxp3 expression in T lymphocytes.
J Immunol
; 190(10): 5030-6, 2013 May 15.
Article
in English
| MEDLINE | ID: mdl-23589618
6.
Evolving regulatory perspectives on digital health technologies for medicinal product development.
NPJ Digit Med
; 6(1): 56, 2023 Mar 29.
Article
in English
| MEDLINE | ID: mdl-36991116
7.
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA).
BMJ Open
; 13(4): e063242, 2023 04 19.
Article
in English
| MEDLINE | ID: mdl-37076159
8.
BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation.
J Immunol
; 184(7): 3514-25, 2010 Apr 01.
Article
in English
| MEDLINE | ID: mdl-20208008
9.
Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany.
Breast
; 49: 246-253, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31918324
10.
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Clin Genitourin Cancer
; 18(5): e629-e642, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32178978
11.
Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition.
Int J Cancer
; 124(6): 1301-11, 2009 Mar 15.
Article
in English
| MEDLINE | ID: mdl-19065652
12.
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Virchows Arch
; 475(5): 599-608, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31267201
13.
Detection of weak receptor-ligand interactions using IgM and J-chain-based fusion proteins.
Eur J Immunol
; 42(5): 1354-6, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22539303
14.
Development and use of IgM/J-chain fusion proteins for characterization of immunoglobulin superfamily ligand-receptor interactions.
Curr Protoc Protein Sci
; 75: 19.24.1-19.24.11, 2014 Feb 03.
Article
in English
| MEDLINE | ID: mdl-24510674
Results
1 -
14
de 14
1
Next >
>>